31 pending office actions • 18 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19394710 | Untitled | Kiniksa Pharmaceuticals GmbH | JONES, DAMERON LEVEST | 1618 | Non-Final OA | |
| 19342035 | Untitled | Ipsen Biopharm Limited | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | |
| 19390312 | Untitled | Praeventix, LLC | MCDOWELL, BRIAN E | 1624 | Non-Final OA | |
| 19390298 | Untitled | Praeventix, LLC | MCDOWELL, BRIAN E | 1624 | Non-Final OA | |
| 19405049 | Untitled | Innocare Pharma Inc. | MCMILLIAN, KARA RENITA | 1623 | Non-Final OA | |
| 19297947 | Untitled | Paragon Therapeutics, Inc. | DAHLE, CHUN WU | 1641 | Non-Final OA | |
| 19242715 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Viridian Therapeutics, Inc. | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | Jun 18, 2025 |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Hangzhou Polymed Biopharmaceuticals, Inc. | MOU, LIYUAN | 1628 | Final Rejection | Mar 21, 2025 |
| 18711074 | TREATMENT OF PAIN | Ipsen Biopharm Limited | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | May 16, 2024 |
| 18711047 | TREATMENT OF VISCERAL PAIN | Ipsen Biopharm Limited | GRASER, JENNIFER E | 1645 | Non-Final OA | May 16, 2024 |
| 18690479 | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | Ipsen Biopharm Limited | SWIFT, CANDICE LEE | 1657 | Non-Final OA | Mar 08, 2024 |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | Non-Final OA | Nov 10, 2023 |
| 18552788 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited | HIBBERT, CATHERINE S | 1658 | Non-Final OA | Sep 27, 2023 |
| 18552599 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | Ipsen Biopharm Limited | BREEN, KIMBERLY CATHERINE | 1657 | Non-Final OA | Sep 26, 2023 |
| 18283579 | BINDING AGENTS TARGETING TUMORS AND/OR IMMUNE CELLS | Kisoji Biotechnology Inc. | DUFFY, BRADLEY | 1643 | Non-Final OA | Sep 22, 2023 |
| 18470726 | TREATMENT OF COMPLEMENT MEDIATED DISEASES AND DISORDERS WITH C3B ANTIBODIES | VISTERRA, INC. | STONEBRAKER, ALYSSA RAE | 1642 | Non-Final OA | Sep 20, 2023 |
| 18466911 | PD-1 AGONIST ANTIBODIES | Otsuka Pharmaceutical Co., Ltd. | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | Sep 14, 2023 |
| 18549871 | MODIFIED CLOSTRIDIAL NEUROTOXINS | Ipsen Biopharm Limited | DUFFY, PATRICIA ANN | 1645 | Non-Final OA | Sep 08, 2023 |
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | 11584022 Canada Inc. | BABSON, NICOLE PLOURDE | 1619 | Non-Final OA | Jun 22, 2023 |
| 18253975 | COMPOSITIONS AND METHODS FOR TREATMENT OF BLEEDING DISORDERS | Band Therapeutics, LLC | NOAKES, SUZANNE MARIE | 1656 | Non-Final OA | May 23, 2023 |
| 18248030 | BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE INCLUDING SYSTEMIC LUPUS ERYTHEMATOUS (SLE) | Xencor, Inc. | DAHLE, CHUN WU | 1641 | Non-Final OA | Apr 05, 2023 |
| 18167529 | METHODS OF USING INTERLEUKIN-2 AGENTS | VISTERRA, INC. | CHATTIN, AMY MARIE | 1643 | Final Rejection | Feb 10, 2023 |
| 18150075 | COMPOSITION COMPRISING RECOMBINANT CLOSTRIDIUM NEUROTOXIN | Ipsen Biopharm Limited | IANNUZO, NATALIE NMN | 1653 | Final Rejection | Jan 04, 2023 |
| 17786708 | POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME | Kisoji Biotechnology Inc. | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | Dec 20, 2022 |
| 18052131 | IMMUNOSILENCING Fc VARIANTS | VISTERRA, INC. | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | Final Rejection | Nov 02, 2022 |
| 17911503 | Treatment of Upper Facial Lines | Ipsen Biopharm Limited | DEVI, SARVAMANGALA | 1645 | Non-Final OA | Sep 14, 2022 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | Final Rejection | Jul 28, 2022 |
| 17812800 | Methods for the Manufacture of Proteolytically Processed Polypeptides | Ipsen Biopharm Limited | KOLKER, DANIEL E | 1645 | Non-Final OA | Jul 15, 2022 |
| 17776533 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | RICCI, CRAIG D | 1611 | Final Rejection | May 12, 2022 |
| 17776531 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | ANDERSON, REBECCA L | 1626 | Final Rejection | May 12, 2022 |
| 17754216 | TREATMENT OF NEUROLOGICAL DISORDERS | Ipsen Biopharm Limited | CHOWDHURY, IQBAL HOSSAIN | 1656 | Non-Final OA | Mar 28, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial